OncogenicHRASmutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome
Authors:
- 24 February 2009
- journal article
- research article
- Published by Hindawi Limited in Human Mutation
- Vol. 30 (3) , 352-362
Abstract
Costello syndrome (CS) is a rare congenital disorder characterized by failure to thrive, craniofacial dysmorphisms, cardiac and skin abnormalities, mental retardation, and predisposition to malignancies. CS is caused by heterozygous gain-of-function mutations in HRAS that also occur as somatic alterations in human tumors. HRAS is one of the three classical RAS proteins and cycles between an active, GTP- and an inactive, GDP-bound conformation. We used primary human skin fibroblasts from patients with CS as a model system to study the functional consequences of HRAS mutations on endogenous signaling pathways. The GTP-bound form of HRAS was significantly enriched in CS compared with normal fibroblasts. Active HRAS is known to stimulate both the RAF-MEK-ERK and the PI3K–AKT signaling cascade. Phosphorylation of MEK and ERK was normal in CS fibroblasts under basal conditions and slightly prolonged after epidermal growth factor (EGF) stimulation. Interestingly, basal phosphorylation of AKT was increased yet more in CS fibroblasts. Moreover, AKT phosphorylation was diminished in the early and enhanced in the late phase of EGF stimulation. Taken together, these results document that CS-associated HRAS mutations result in prolonged signal flux in a ligand-dependent manner. Our data suggest that altered cellular response to growth factors rather than constitutive activation of HRAS downstream signaling molecules may contribute to some of the clinical features in patients with CS. Hum Mutat 0,1–11, 2008.Keywords
This publication has 70 references indexed in Scilit:
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activationJournal of Medical Genetics, 2007
- The cardiofaciocutaneous syndromeJournal of Medical Genetics, 2006
- GTPase activating proteins: structural and functional insights 18 years after discoveryCellular and Molecular Life Sciences, 2005
- Germline mutations in HRAS proto-oncogene cause Costello syndromeNature Genetics, 2005
- Tumor predisposition in Costello syndromeAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2005
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- The Guanine Nucleotide-Binding Switch in Three DimensionsScience, 2001
- The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras MutantsScience, 1997
- Phosphatidylinositol-3-OH kinase direct target of RasNature, 1994